Memantine Grindeks (Memantine Hydrochloride)

Memantine Grindeks belongs to the NMDA receptor antagonist class and is used in the management of Alzheimer’s disease.

• Alzheimer’s disease (moderate to severe): Improves cognition and functional abilities in patients with established disease.
• Alzheimer’s disease (behavioral symptoms): May reduce agitation and aggression associated with the condition.
• Alzheimer’s disease (overall progression): May help slow functional decline when used with standard care.

• Memantine Hydrochloride acts as a non‑competitive antagonist at the NMDA (N‑methyl‑D‑aspartate) receptor. By binding to the receptor-associated ion channel, it reduces excessive calcium influx caused by glutamate over‑activation, thereby limiting excitotoxic neuronal injury that contributes to cognitive decline in Alzheimer’s disease.

Memantine is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Headache: mild to moderate pain in the head region.
• Constipation: reduced bowel movements or hard stools.
• Confusion: transient disorientation or difficulty concentrating.
• Fatigue: feeling unusually tired or low in energy.
• Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects

• Seizures: convulsive episodes requiring immediate medical attention.
• Cardiac arrhythmia: irregular heart rhythms that may be symptomatic.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hepatic injury: signs of liver dysfunction including jaundice.
• Suicidal thoughts: emergence of depressive ideation or self‑harm urges.
• Psychosis: new or worsening hallucinations or delusional thinking.

When prescribing Memantine Grindeks, clinicians should consider several safety aspects.

• Renal impairment: dose adjustment may be required due to reduced clearance.
• Hepatic impairment: monitor liver function tests regularly.
• History of seizures: use with caution as the drug may lower seizure threshold.
• Concurrent NMDA antagonists: avoid combined use to prevent additive neurotoxicity.
• Pregnancy: safety category unknown; avoid unless potential benefit justifies the risk.
• Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Memantine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

• Amantadine: additive NMDA antagonism may increase neurotoxic risk.
• Other NMDA antagonists (e.g., ketamine): combined use can lead to excessive inhibition.
• Strong CYP450 inhibitors (e.g., quinidine): may raise memantine plasma concentrations.

Moderate Interactions (Monitor Closely)

• Anticholinesterases (e.g., donepezil): may require dose titration for optimal effect.
• Diuretics (e.g., furosemide): monitor electrolytes and renal function.
• Antihypertensives: memantine may enhance blood‑pressure‑lowering effects.